NASDAQ:ADAG

Adagene Stock Forecast, Price & News

$13.89
+0.46 (+3.43 %)
(As of 04/13/2021 10:10 AM ET)
Add
Compare
Today's Range
$13.89
Now: $13.89
$13.89
50-Day Range
$14.48
MA: $20.60
$26.32
52-Week Range
$13.05
Now: $13.89
$31.83
Volume30 shs
Average Volume97,641 shs
Market Capitalization$601.20 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its products include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in preclinical stage used in the treatment of cancers; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of metastatic solid tumors. The company was founded in 2011 and is headquartered in Suzhou, China.
Adagene logo

Industry, Sector and Symbol

Industry --
Sub-IndustryN/A
Sector--
Current SymbolNASDAQ:ADAG
CUSIPN/A
CIKN/A
Phone86 512 8777 3632
Employees199
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$601.20 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

1.70 out of 5 stars

-- Sector

2nd out of 266 stocks

-- Industry

2nd out of 268 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$13.89
+0.46 (+3.43 %)
(As of 04/13/2021 10:10 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADAG News and Ratings via Email

Sign-up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Adagene (NASDAQ:ADAG) Frequently Asked Questions

Is Adagene a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adagene in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Adagene stock.
View analyst ratings for Adagene
or view top-rated stocks.

What stocks does MarketBeat like better than Adagene?

Wall Street analysts have given Adagene a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Adagene wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for ADAG?

3 brokers have issued 1 year target prices for Adagene's shares. Their forecasts range from $29.00 to $34.00. On average, they expect Adagene's stock price to reach $32.00 in the next twelve months. This suggests a possible upside of 130.4% from the stock's current price.
View analysts' price targets for Adagene
or view top-rated stocks among Wall Street analysts.

Who are Adagene's key executives?

Adagene's management team includes the following people:
  • Dr. Peter P. Luo, Co-Founder, CEO & Chairman (Age 55)
  • Mr. Man Kin Tam M.B.A., CFO & Director (Age 44)
  • Dr. Hua Gong M.D., Ph.D., COO & Head of Clinical Devel. and Precision Medicine (Age 53)
  • Dr. Fangyong Du Ph.D., Chief Technology Officer (Age 51)
  • Dr. Jc Xu M.D., Ph.D., Chief Scientific Officer (Age 56)
  • Dr. Yu Ren Ph.D., Chief Strategy & Corp. Devel. Officer (Age 46)
  • Dr. Qinghai Zhao, Chief Manufacturing Officer (Age 60)
  • Ms. Yan Li M.B.A., Sr. VP of Bioinformatics & Information Technology (Age 46)
  • Ms. Xiaohong She, Sr. VP & Head of Clinical Operations (Age 54)
  • Dr. Guizhong Liu Ph.D., Head of Biology & Pharmacology (Age 50)

Who are some of Adagene's key competitors?

When did Adagene IPO?

(ADAG) raised $133 million in an IPO on Tuesday, February 9th 2021. The company issued 7,400,000 shares at $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies served as the underwriters for the IPO and China Renaissance was co-manager.

What is Adagene's stock symbol?

Adagene trades on the NASDAQ under the ticker symbol "ADAG."

When does the company's lock-up period expire?

Adagene's lock-up period expires on Monday, August 9th. Adagene had issued 7,354,000 shares in its initial public offering on February 9th. The total size of the offering was $139,726,000 based on an initial share price of $19.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

How do I buy shares of Adagene?

Shares of ADAG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adagene's stock price today?

One share of ADAG stock can currently be purchased for approximately $13.89.

How much money does Adagene make?

Adagene has a market capitalization of $601.20 million.

How many employees does Adagene have?

Adagene employs 199 workers across the globe.

What is Adagene's official website?

The official website for Adagene is www.adagene.com.

How can I contact Adagene?

The company can be reached via phone at 86 512 8777 3632.


This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.